Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot colon cancer in young adults before It's too late

NCT ID NCT06342401

Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study is developing a blood test that uses tiny particles called exosomes and machine learning to detect colorectal cancer in people under 50. The test looks for specific microRNA patterns in the blood. Researchers will compare results from 400 people—some with cancer and some without—to see how accurate the test is. If it works, it could offer a non-invasive way to catch this cancer early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test measuring microRNA from exosomes and cell-free particles
What this could lead to
If successful, this could provide a simple, non-invasive blood test to catch early-onset colorectal cancer sooner, potentially saving lives.
What could go wrong
This is still an early-stage study with 400 participants. The test may not be accurate enough for widespread use, and results need validation in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals younger than 50 years of age who were diagnosed with colorectal cancer before the age of 50 (cases) or were free from colorectal cancer at the time of study inclusion (controls)

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stage I, II, III, IV colorectal cancer (TNM classification, 8th edition) diagnosed before the age of 50 (EOCRC cases) * Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment * Colonoscopy-proven cancer-free status at the time of study inclusion (Non-disease controls) Exclusion Criteria: * Hereditary colorectal cancer syndromes (identified through genetic testing) * Inflammatory bowel diseases * Lack of written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal adenocarcinoma colorectal cancer colorectal neoplasm rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal adenocarcinoma Colorectal cancer Colorectal cancer stage I Colorectal cancer stage II Colorectal cancer stage III Colorectal cancer stage IV Colorectal neoplasms Colorectal neoplasms malignant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barcelona University

    RECRUITING

    Barcelona, Spain

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

  • Colorectal Surgery, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona UAB

    RECRUITING

    Barcelona, Spain

  • IRCCS San Raffaele

    RECRUITING

    Milan, Italy

  • Kawasaki University

    RECRUITING

    Kawasaki, Japan

  • Mie University

    RECRUITING

    Mie, Japan

  • National Cancer Center Hospital

    RECRUITING

    Tokyo, Japan

  • Salamanca Biomedical Research Institute

    RECRUITING

    Madrid, Spain

  • Surgery Department, Hospital del Mar, Barcelona, Spain

    RECRUITING

    Barcelona, Spain

  • Tokyo Medical and Dental University

    RECRUITING

    Tokyo, Japan

  • University of La Laguna

    RECRUITING

    San Cristóbal de La Laguna, Spain

  • University of Salamanca-SACYL-CSIC, Salamanca, Spain

    RECRUITING

    Salamanca, Spain

  • Yamagata University

    RECRUITING

    Yamagata, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.